Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?
Morcos
S K
SK
Department of Diagnostic Imaging, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield S5 7AU, UK. sameh.morcos@sth.nhs.uk
D003287:Contrast Media / Q000009:adverse effects* / Q000737:chemistry; D005355:Fibrosis / Q000139:chemically induced; D005682:Gadolinium / Q000009:adverse effects* / Q000737:chemistry; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D012595:Scleroderma, Systemic / Q000139:chemically induced*; D012867:Skin / Q000473:pathology*
D003287:Contrast Media; D005682:Gadolinium